Glucagon‐like peptide‐1 (GLP‐1) agonists are medications primarily used to manage type 2 diabetes mellitus (T2DM); however, they have been shown to improve the risk of cardiovascular, neurogenerative, and polycystic ovaries diseases, etc.90 This evidence concerns the gene GLP1R and type 2 diabetes mellitus.